Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma

• DOI: 10.1097/meg.0b013e328346d505
• Publication Date: 2011-04-30T05:09:11Z
• Authors: Myeong Jun Song; Chung-Hwa Park; Jin Dong Kim; Hee Yeon Kim; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Ho Jong Chun; Byung Gil Choi; Hae Giu Lee
• Keywords: Lipiodol; Clinical endpoint; Transcatheter arterial chemoembolization

Objective Lipiodol transcatheter arterial chemoembolization (TACE) is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed enhance drug delivery the tumor and reduce its systemic availability. The purpose of this study was compare efficacy safety intra-arterial injection DEB loaded with doxorubicin versus conventional, Lipiodol-based TACE regimens in Asian patients HCC. Methods designed as case–control, single-institution clinical trial. Twenty HCC who received 50 mg ('cases') were matched 20 had undergone conventional ('controls'). primary endpoint response at 1 month according modified Response Evaluation Criteria Solid Tumors. liver toxicity. Results rate objective by Tumors 85% (17 patients) arm 30% (six (P=0.001). Subgroup analyses conducted large (>5 cm) or multinodular confirmed significantly higher rates receiving compared those treated (P=0.003 P=0.005, respectively). At dose doxorubicin, there no statistically significant difference toxicity between (P>0.05). Conclusion In HCC, treatment offers distinct advantage regimens.